Written question asked by Steve Yemm (Labour) on Wednesday, 13 May 2026, in the House of Commons. It was due for an answer on Monday, 18 May 2026. It was answered by Sharon Hodgson (Labour) on Tuesday, 26 May 2026 on behalf of the Department of Health and Social Care.
Metabolic Dysfunction-associated Steatohepatitis
- Question
-
To ask the Secretary of State for Health and Social Care, whether the transformation of liver services programme led by the NHS England Hepatobiliary and Pancreas Clinical Reference Group will include a specific workstream to help address the unmet clinical need in metabolic dysfunction-associated steatohepatitis.
- Answer
-
The transformation of liver services programme includes a number of workstreams including patient pathways relating to metabolic associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH).
NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing National Institute for Health and Care Excellence appraisal process.
Secondary information
- Type
- Written question
- Reference
- 621
- Session
- 2026-27
- Subjects
- Health services Metabolic dysfunction-associated steatohepatitis
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-05-26 10:41:02 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/621
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/621
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/621